BioSpace: To Realize AI’s Benefits, Don’t Lose Sight of Fundamentals
Thomas Swalla, CEO of Dotmatics, emphasizes in BioSpace that while AI is transforming the biopharma industry, organizations must balance adopting advanced AI technologies with maintaining core scientific fundamentals to fully realize AI’s potential and drive groundbreaking advancements.
In this feature from BioSpace, Thomas Swalla, CEO at Dotmatics, discusses how AI is revolutionizing the biopharma industry. The article provides expert insights on balancing cutting-edge technology with core scientific principles to unlock AI's full potential. It highlights critical strategies for integrating AI in biopharma while maintaining a strong foundation in the basics.
The key takeaway is the importance of not losing sight of fundamental scientific practices as organizations adopt and implement AI-driven solutions. Maintaining this balance is essential for leveraging AI to achieve groundbreaking advancements in the field.
Related
NBC Las Vegas: AI is Accelerating Drug Discovery and Vaccine Development
In an NBC Las Vegas interview, Phil Mounteney, VP of Science and Technology at Dotmatics, explains how AI is transforming drug discovery and vaccine development by accelerating research timelines, reducing costs, enhancing drug safety through advanced data analysis, and optimizing development pipelines for faster and more efficient medical breakthroughs post-COVID.
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
How AI is Transforming Drug Discovery
Dotmatics executives Kalim Saliba and Steve Tharp explain in an NBC News Boston feature how AI is revolutionizing drug discovery by enabling researchers to navigate complex data more efficiently, significantly reducing development time and costs, and accelerating the creation of safer, personalized medicines.
NBC Louisiana: How AI is Accelerating Drug Discovery
In an NBC Louisiana feature, Dotmatics’ VP Phil Mounteney explained how AI is revolutionizing drug discovery by significantly reducing development time from up to ten years to potentially half, enhancing efficiency in analyzing vast data sets while ensuring data privacy by keeping sensitive information secure and in-house.
KRON TV: AI in Medicine From Research Assistant to Predictive Partner
In a KRON-TV interview, Dotmatics VP Phil Mounteney discusses how AI is evolving from a research assistant automating data tasks to a predictive partner that accelerates drug discovery by identifying new targets, designing molecules, and enabling personalized therapies, ultimately reducing costs and time to market while expanding patient access to safer, tailored medicines.
Dotmatics helping scientists make better drugs in less time using AI
Dotmatics executives Kalim Saliba and Steve Tharp explain in a CBS News Boston feature how the company leverages artificial intelligence to transform pharmaceutical drug discovery by providing innovative solutions that accelerate and improve the efficiency of scientific research and development in the life sciences sector.